Press Releases

 
Press Releases
  Date Title View
Nov 17, 2016
DURHAM, N.C., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering and developing medicines that improve outcomes for immunocompromised patients,  presented data from a preclinical study of intravenous (IV) brincidofovir to determine tissue distribution after single IV or oral administration of the dru...
Nov 9, 2016
DURHAM, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present a corporate overview at the following upcoming conferences: Sti...
Nov 7, 2016
- Brincidofovir IV Single and Multiple Dose Data Expected to Report Out in 2017 - - Comparative Adenovirus Trial with Oral Brincidofovir Expected to Start in 2017 - - CMX521 for Norovirus Advancing Toward the Clinic - - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopha...
Oct 31, 2016
DURHAM, N.C., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast on Monday, November 7, 2016 at 8:30 a.m. ET to report financial results for the third quarter ended Septemb...
Oct 27, 2016
- Results Show Early Virologic Response Associated with Better Overall Survival - DURHAM, N.C., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced the presentation of detailed 24-week interim results from the AdVise trial of br...
Sep 6, 2016
DURHAM, N.C., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H, Chief Executive Officer of Chimerix, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at...
Aug 8, 2016
- European Commission Granted Orphan Drug Designation for Brincidofovir for the Treatment of Adenovirus - - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported financial results a...
Aug 1, 2016
DURHAM, N.C., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2016 at 8:30 a.m. ET to report financial results for the second quarter ended Jun...
Jun 7, 2016
DURHAM, N.C., June 07, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will participate in a panel focused on North Carolina's role in biodefense pr...
May 9, 2016
- Maintains strong financial position with $314.5 million in capital at quarter end - - Company to hold conference call at 8:30am ET today - DURHAM, N.C., May 09, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported top-line results from an in...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase